Feb 6 | News
NEW YORK (AP) — Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing.
|
Jan 19 | News
Aptalis Pharma, a global specialty pharmaceutical company focused on gastrointestinal diseases and cystic fibrosis, today announced that the FDA has approved a New Drug Application (NDA) for Gilead Sciences, Inc.'s Viread (tenofovir disoproxil fumarate) oral powder in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-5.
|
Jan 12 | News
FOSTER CITY, Calif. (AP) — Gilead Sciences has acquired about 95 percent of the outstanding shares in Pharmasset as it draws closer to closing its $11 billion deal for the drug developer.
|
Dec 8 2011 | News
Gilead Sciences, Inc. announced today that it will donate 445,000 vials of AmBisome(R) (amphotericin B liposome for injection) over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar.
|
Nov 23 2011 | News
Shares of Gilead Sciences climbed as much as 6.9 percent Tuesday after tumbling 9 percent Monday to a 52-week low on news that it was buying Pharmasset.
|
Nov 21 2011 | News
FOSTER CITY, Calif. (AP) — Gilead Sciences says it will spend $11 billion to buy drug developer Pharmasset at a price more than 88 percent over the stock's latest closing price in a bet on its experimental hepatitis C treatments.
|
Nov 16 2011 | News
NEW YORK (AP) — Gilead Sciences Inc. and Johnson & Johnson's Tibotec unit said Tuesday they will collaborate to develop a new HIV pill that combines Tibotec's Prezista with Gilead's drug Emtriva and two experimental drugs.
|
Oct 27 2011 | News
TRENTON, N.J. (AP) — Bristol-Myers Squibb Co. will develop a once-a-day pill to treat the HIV virus that combines its popular Reyataz with an experimental drug from Gilead Sciences Inc., the companies said Wednesday.
|
Oct 6 2011 | News
FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. said Wednesday that it has obtained the global rights to develop and bring to market an HIV treatment from German pharmaceutical company Boehringer Ingelheim.
|
Aug 19 2011 | News
The AIDS Healthcare Foundation (AHF) is claiming that the recent campaign by Gilead Sciences Inc. to obtain approval by the FDA for Truvada as PrEP (pre-exposure prophylaxis) has led to a "black market" for the drug in Florida.
|